Vascular disease, ESRD, and death: Interpreting competing risk analyses

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 10, 2012, Pages 1606-1614

  Grams, Morgan E ^a,b   Coresh, Josef ^a,b   Segev, Dorry L ^a,b   Kucirka, Lauren M ^a   Tighiouart, Hocine ^c   Sarnak, Mark J ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEINURIA; RISK ASSESSMENT; SURVIVAL; VASCULAR DISEASE;

AGE FACTORS; COMORBIDITY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; VASCULAR DISEASES;

EID: 84867240319     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03460412     Document Type: Article

References (36)

1. Agarwal R, Bunaye Z, Bekele DM, Light RP: Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol 28: 569-575, 2008
2. Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH; FinnDiane Study Group: Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 22: 537-544, 2011
3. Newsome BB, McClellan WM, Allison JJ, Eggers PW, Chen SC, Collins AJ, Kiefe CI, Coffey CS, Warnock DG: Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction. Am J Kidney Dis 52: 251-261, 2008
4. Eriksen BO, Ingebretsen OC: The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney Int 69: 375-382, 2006
5. Obi Y, Kimura T, Nagasawa Y, Yamamoto R, Yasuda K, Sasaki K, Kitamura H, Imai E, Rakugi H, Isaka Y, Hayashi T: Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol 5: 1558-1565, 2010
6. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659-663, 2004
7. Gullion CM, Keith DS, Nichols GA, Smith DH: Impact of comorbidities on mortality in managed care patients with CKD. Am J Kidney Dis 48: 212-220, 2006
8. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489-495, 2005
9. Fick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J AmSoc Nephrol 5: 2048-2056, 1995
10. Berhane AM, Weil EJ, Knowler WC, Nelson RG, Hanson RL: Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol 6: 2444-2451, 2011
11. Costacou T, Fried L, Ellis D, Orchard TJ: Sex differences in the development of kidney disease in individuals with type 1 diabetes mellitus: A contemporary analysis. Am J Kidney Dis 58: 565-573, 2011
12. McClellan WM, Warnock DG, Judd S, Muntner P, Kewalramani R, Cushman M, McClure LA, Newsome BB, Howard G: Albuminuria and racial disparities in the risk for ESRD. J AmSoc Nephrol 22: 1721-1728, 2011
13. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE: The analysis of failure times in the presence of competing risks. Biometrics 34: 541-554, 1978
14. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496-509, 1999
15. Yang JG, Li J, Lu C, Hasimu B, Yang Y, Hu D: Chronic kidney disease, all-cause mortality and cardiovascular mortality among Chinese patients with established cardiovascular disease. J Atheroscler Thromb 17: 395-401, 2010
16. Drüeke TB, Massy ZA: Atherosclerosis in CKD: Differences from the general population. Nat Rev Nephrol 6: 723-735, 2010
17. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, Salem D, Sarnak MJ, Weiner DE: Cardiovascular disease and subsequent kidney disease. Arch Intern Med 167: 1130-1136, 2007
18. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensinconverting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials. Lancet 368: 581-588, 2006
19. Shastri S, Tangri N, Tighiouart H, Beck GJ, Vlagopoulos P, Ornt D, Eknoyan G, Kusek JW, Herzog C, Cheung AK, Sarnak MJ: Predictors of sudden cardiac death: A competing risk approach in the hemodialysis study. Clin J AmSoc Nephrol 7: 123-130, 2012
20. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
21. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J: Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 20: 2617-2624, 2009
22. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative metaanalysis. Lancet 375: 2073-2081, 2010
23. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377: 2181-2192, 2011
24. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G; Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330: 877-884, 1994
25. Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-Connell AT, Bakris GL, McCullough PA: Comparison of the CKD epidemiology collaboration (CKD-EPI) and modification of diet in renal disease (MDRD) study equations: Risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 57 [Suppl 2]: S9-S16, 2011
26. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J: Risk implications of the new CKD Epidemiology Collaboration (CKDEPI) equation compared with the MDRD Study equation for estimated GFR: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 55: 648-659, 2010
27. Bainton D, Sweetnam P, Baker I, Elwood P: Peripheral vascular disease: Consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J 72: 128-132, 1994
28. Gattellari M, Goumas C, Garden F, Worthington JM: Relative survival after transient ischaemic attack: Results from the Program of Research Informing Stroke Management (PRISM) study. Stroke 43: 79-85, 2012
29. Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK: ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus theUnited States. Kidney Int 50: 1013-1018, 1996
30. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ: Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 204: 298-303, 2009
31. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18: 695-706, 1999
32. Verduijn M, Grootendorst DC, Dekker FW, Jager KJ, le Cessie S: The analysis of competing events like cause-specific mortality-beware of the Kaplan-Meier method. Nephrol Dial Transplant 26: 56-61, 2011
33. Pintilie M: Analysing and interpreting competing risk data. Stat Med 26: 1360-1367, 2007
34. De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R; SIN-TABLE CKD Study Group: Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 6: 2421-2428, 2011
35. Sekkarie MA, Moss AH: Withholding and withdrawing dialysis: The role of physician specialty and education and patient functional status. Am J Kidney Dis 31: 464-472, 1998
36. Merkin SS, Cavanaugh K, Longenecker JC, Fink NE, Levey AS, Powe NR: Agreement of self-reported comorbid conditions with medical and physician reports varied by disease among endstage renal disease patients. J Clin Epidemiol 60: 634-642, 2007